Every Form 4 that Surmodics, Inc. (SRDX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SRDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRDX filings page.
Surmodics, Inc. (SRDX) senior executive Charles W. Olson reported the automatic cash-out of his equity holdings in connection with the company’s merger with BCE Parent, LLC. At the merger’s effective time, each share of Surmodics common stock was cancelled and converted into the right to receive $43.00 per share in cash, and all of Olson’s restricted stock units vested and became entitled to the same cash consideration.
The filing shows that 51,478 shares of common stock held directly and 800 shares held through an IRA were disposed of, and multiple employee stock options with exercise prices between $33.64 and $56.63 covering various share amounts were cancelled. Each option was converted into a cash right equal to the number of underlying shares multiplied by the excess of the $43.00 merger consideration over the option’s exercise price. As a result of the merger, Olson no longer beneficially owns any Surmodics common stock.
Surmodics, Inc. (SRDX) completed a cash merger in which all common shares were converted into the right to receive $43.00 per share in cash. This Form 4 reports that the company’s VP Finance and Corporate Controller had all 8,155 shares of common stock disposed of in connection with the transaction.
Multiple employee stock options with exercise prices ranging from $33.64 to $43.93 covering 1,740, 1,862, 4,584, 4,810 and 3,160 underlying shares were cancelled at the effective time of the merger and converted into cash based on the excess of the $43.00 merger consideration over each option’s exercise price. Following these transactions, the reporting person no longer beneficially owns any Surmodics common stock.
Surmodics Inc. completed a merger in which all outstanding common stock was converted into cash at $43.00 per share. Under the merger agreement, Surmodics became a wholly owned subsidiary of BCE Parent, LLC after BCE Merger Sub, Inc. merged into the company.
The reporting person, a senior vice president and general counsel, had all restricted stock units vest immediately before the effective time and became entitled to receive the same $43.00 per share cash consideration for those RSUs. All employee stock options with exercise prices such as $36.23, $37.44, $43.93, $36.13 and $33.64 were cancelled and converted into a cash payment equal to the number of underlying shares multiplied by the excess of $43.00 over the option exercise price.
As a result of these transactions, the reporting person no longer beneficially owns any Surmodics common stock or related stock options.
Surmodics Inc. (SRDX) filed a Form 4 for its SVP of Vascular Interventions showing the completion mechanics of its merger with BCE Parent, LLC. At the merger’s effective time, each share of Surmodics common stock was cancelled and converted into the right to receive $43.00 per share in cash, subject to tax withholding. All restricted stock units held by the executive vested immediately before closing and will receive the same cash consideration.
The filing also shows that multiple employee stock options with exercise prices ranging from $33.64 to $56.63 were cancelled and converted into cash based on the excess of the $43.00 merger price over each option’s exercise price, if any. Following these transactions, the reporting person no longer beneficially owns any Surmodics common stock or related options.
Surmodics Inc. (SRDX) director reports full cash-out following merger. The filing describes the closing of a merger in which BCE Merger Sub, Inc. merged into Surmodics, Inc., making Surmodics a wholly owned subsidiary of BCE Parent, LLC. At the effective time, each share of Surmodics common stock was cancelled and converted into the right to receive $43.00 per share in cash, before taxes.
All restricted stock units held by the reporting person vested immediately before the merger and are entitled to the same $43.00 per-share cash consideration. The director disposed of 40,183 shares of common stock and multiple employee stock options covering several thousand shares at exercise prices ranging from $28.98 to $55.24, which were cancelled and converted into their in-the-money cash value. Following these transactions, the reporting person no longer beneficially owns any Surmodics common stock or stock options.
Surmodics, Inc. (SRDX) completed a cash merger in which all outstanding common shares held by the reporting director were converted into the right to receive $43.00 per share in cash, subject to tax withholding. The filing shows that all restricted stock units held by this person vested immediately before the merger’s effective time and will be paid the same cash amount per share.
The director’s outstanding employee stock options, with exercise prices ranging from $28.98 to $55.24 and covering several option grants, were cancelled and converted into cash equal to the in-the-money value based on the $43.00 merger consideration. Following these transactions, the reporting person no longer beneficially owns any shares of Surmodics common stock.
Surmodics, Inc. (SRDX) reported a director-level Form 4 tied to the company’s go-private merger. Under a Merger Agreement among Surmodics, BCE Parent, LLC and BCE Merger Sub, Inc., Merger Sub merged into Surmodics, which now operates as a wholly owned subsidiary of BCE Parent.
At the effective time of the merger, each share of Surmodics common stock was cancelled and converted into the right to receive $43.00 per share in cash, before taxes. All restricted stock units held by the reporting person vested immediately before closing and are entitled to the same $43.00 cash consideration per underlying share.
All reported employee stock options with exercise prices such as $55.24, $39.58, $53.86, $41.81, $28.98 and $31.89 were cancelled and converted into cash equal to the number of option shares multiplied by the excess of $43.00 over the option’s exercise price, subject to tax withholding. As a result of the merger, the reporting person no longer beneficially owns any Surmodics common stock.
Surmodics, Inc. (SRDX) filed a Form 4 showing that a director’s equity was cashed out in connection with the company’s merger. On 11/19/2025, all shares of Surmodics common stock held by the reporting person were cancelled and converted into the right to receive $43.00 per share in cash under a previously signed merger agreement with BCE Parent, LLC.
All restricted stock units held by the director vested immediately before the merger’s effective time and are also entitled to the $43.00 per-share cash consideration. In addition, multiple unexercised employee stock options with exercise prices ranging from $28.98 to $55.24 were cancelled and converted into cash equal to the spread between the $43.00 merger consideration and each option’s exercise price, subject to tax withholdings. Following these transactions, the reporting person no longer beneficially owns any Surmodics common stock.
Surmodics, Inc. (SRDX) reported that its Chief Financial Officer, listed as the reporting person, no longer holds any company stock or stock options following the completion of a previously agreed merger. Under the merger with BCE Parent, LLC, each share of Surmodics common stock was automatically cancelled and converted into the right to receive $43.00 in cash per share, subject to tax withholdings.
All restricted stock units held by the reporting person vested immediately before the merger’s effective time and were also converted into the cash merger consideration. Multiple outstanding employee stock options with exercise prices ranging from $33.64 to $56.63 per share were cancelled and converted into cash equal to the number of shares underlying each option times the amount by which the $43.00 merger price exceeded the option’s exercise price. After these transactions, the reporting person holds no Surmodics common stock or derivative securities.
Surmodics Inc. (SRDX) reported a Form 4 transaction for its SVP of HR and President IVD tied to the closing of its merger with BCE Parent, LLC. At the merger effective time, each share of Surmodics common stock was cancelled and converted into the right to receive $43.00 per share in cash, subject to tax withholding. All restricted stock units held by the insider vested immediately before the effective time and are also entitled to the same cash consideration. Following the merger, the insider reported owning 0 shares of common stock.
The filing also shows that multiple employee stock options with exercise prices ranging from $33.64 to $56.63 per share were cancelled on 11/19/2025 and converted into cash rights equal to the in-the-money value, again subject to tax withholding.
Surmodics Inc. (SRDX) completed a cash merger in which all outstanding common shares were converted into the right to receive $43.00 per share in cash, without interest and subject to tax withholding. For President & CEO and director Gary R. Maharaj, the filing shows that his remaining 192,056 shares of common stock were disposed of in connection with the merger, leaving him with no beneficial ownership of Surmodics common stock.
The filing also details that multiple employee stock options held by Maharaj, covering tens of thousands of shares each at exercise prices between $33.64 and $56.63, were cancelled and converted into cash. Each option is being settled for cash equal to the number of shares subject to the option multiplied by the excess of the $43.00 merger consideration over the option’s exercise price, subject to tax withholdings.